Last updated: October 5, 2026
Imuran is the original branded formulation of azathioprine, an immunosuppressant used primarily in organ transplantation and autoimmune disease. Its commercial profile is mature and largely genericized. The brand has limited strategic value in the United States because regulatory exclusivity expired decades ago, generic azathioprine is widely available, and treatment has shifted toward tacrolimus, mycophenolate, biologics, and targeted immunomodulators. Public disclosures do not provide a reliable standalone revenue series for Imuran, so the financial trajectory is best assessed through molecule-level demand, generic pricing, and therapeutic substitution.
What is Imuran and how is azathioprine used?
Imuran contains azathioprine, a thiopurine prodrug that is converted to 6-mercaptopurine and suppresses purine synthesis. The drug inhibits lymphocyte proliferation and is used as a maintenance immunosuppressant.
| Attribute |
Imuran and azathioprine |
| Active ingredient |
Azathioprine |
| Drug class |
Thiopurine immunosuppressant |
| Original branded product |
Imuran |
| U.S. FDA approval |
1968, according to the current U.S. prescribing information |
| Main approved uses |
Renal transplantation; rheumatoid arthritis |
| Common off-label uses |
Inflammatory bowel disease, autoimmune hepatitis, lupus, dermatologic and rheumatologic disorders |
| Dosage forms |
Oral tablets; injectable azathioprine products are also available in certain markets |
| Primary commercial status |
Mature, largely generic market |
| Key safety issues |
Myelosuppression, hepatotoxicity, infection risk, malignancy risk, hypersensitivity |
| Pharmacogenetic relevance |
TPMT and NUDT15 activity affects toxicity risk |
The FDA label identifies Imuran for prevention of renal allograft rejection and treatment of active rheumatoid arthritis. In clinical practice, azathioprine is also used for steroid-sparing treatment in inflammatory bowel disease and other immune-mediated conditions, although many uses are not covered by the original branded indication set (FDA, 2024a).
When did Imuran lose exclusivity?
Imuran lost meaningful U.S. market exclusivity many years ago. The product was approved in the late 1960s, and azathioprine tablets have been available from multiple generic manufacturers for decades.
The relevant commercial event is not a recent patent expiry. It is the long-term transition from branded Imuran to low-cost generic azathioprine. Current U.S. prescribing and reimbursement are therefore driven by generic availability, pharmacy contracting, wholesaler supply, and clinical substitution.
U.S. exclusivity timeline
| Milestone |
Approximate timing |
Commercial effect |
| Original U.S. approval of Imuran |
1968 |
Established azathioprine as an approved immunosuppressant |
| Generic azathioprine market development |
Decades ago |
Reduced brand pricing power |
| Brand-generic substitution |
Long established |
Shifted volume away from Imuran |
| Current market |
Mature generic era |
Limited role for brand-based exclusivity |
| Current lifecycle position |
Post-exclusivity |
Competition depends on supply, price, and clinical familiarity |
The FDA Orange Book lists approved products and regulatory information but does not create new commercial exclusivity for an old small-molecule product. No current Imuran patent estate appears to provide a meaningful U.S. barrier to generic azathioprine. The commercial protection once associated with the original product has therefore expired in practical terms (FDA, 2024b).
What patents protect Imuran and azathioprine?
No active composition-of-matter patent is expected to protect azathioprine in the United States. The molecule was discovered and commercialized more than half a century ago, placing any original patent protection well beyond its normal term.
| IP category |
Current relevance to Imuran |
| Azathioprine composition patent |
Expired |
| Original Imuran formulation patents |
Expired or commercially immaterial |
| Tablet-strength patents |
Not a meaningful barrier |
| Method-of-use patents |
No known broad, enforceable exclusivity comparable to a modern specialty product |
| Manufacturing know-how |
Potentially relevant to quality and supply, but not a barrier to ordinary generic entry |
| Orange Book-listed patents |
No meaningful current patent barrier is expected |
The residual intellectual-property value lies mainly in manufacturing controls, impurity management, analytical methods, and supply-chain reliability. Those factors can affect product quality and regulatory approval, but they do not recreate branded exclusivity.
What formulations are protected by Imuran patents?
The original oral tablet formulation is not commercially protected by a modern formulation patent estate. Generic manufacturers can produce azathioprine tablets after satisfying FDA quality, bioequivalence, current good manufacturing practice, and application requirements.
There is no evidence that a proprietary extended-release, depot, transdermal, or other differentiated Imuran delivery system has generated a material new exclusivity period. The product remains commercially centered on conventional oral azathioprine.
What is the Orange Book status of Imuran?
Imuran is an old, approved small-molecule product whose commercial position is dominated by generic competition. Orange Book relevance is limited to identifying the reference product and any listed patent or exclusivity information associated with the applicable NDA.
For commercial analysis, the key distinction is between:
- The original Imuran reference product.
- Authorized or branded generic versions.
- Abbreviated new drug application products containing azathioprine.
- Non-U.S. products marketed under different brand names.
A generic manufacturer does not need to overcome a current Imuran patent barrier to enter the U.S. market if no enforceable listed patent blocks approval. The principal barriers are regulatory compliance, manufacturing capacity, pharmacovigilance, and reliable distribution.
Which companies are challenging Imuran through generic entry?
Generic competition is not a conventional Paragraph IV campaign today. Azathioprine generic entry occurred long ago, and the market has moved beyond the initial patent-challenge phase.
Potential suppliers vary by market and time. U.S. azathioprine tablets have historically been supplied by multiple generic companies and contract manufacturers. Brand ownership and distribution arrangements also differ across jurisdictions. Because generic companies frequently change manufacturing sites, labelers, and supply arrangements, a static list of suppliers is less useful than an analysis of the FDA approval database and current National Drug Code records.
What does Paragraph IV risk mean for Imuran?
Paragraph IV risk is effectively historical for Imuran. A Paragraph IV certification would have been relevant when a generic applicant challenged an unexpired Orange Book patent. For an old azathioprine product with no commercially meaningful remaining patent term, generic entry risk is already realized.
The market risks now involve:
- Manufacturing interruptions.
- Active pharmaceutical ingredient supply.
- FDA inspections or warning letters.
- Product recalls.
- Wholesaler concentration.
- Price erosion.
- Substitution by newer immunosuppressants.
What patent litigation affects Imuran?
Patent litigation is not a major current market driver for Imuran. The product’s age, generic availability, and absence of meaningful current composition-of-matter protection reduce the incentive for branded patent litigation.
Any current disputes would more likely involve:
- Generic manufacturing quality.
- Product liability.
- Distribution or trademark rights.
- Supply contracts.
- Regulatory enforcement.
- Individual prescribing or reimbursement disputes.
Those issues differ from a conventional branded-drug patent dispute involving an active pharmaceutical patent and a blocked generic launch.
What is the FDA regulatory status of Imuran?
The FDA-approved product is supported by a long-established safety and efficacy record, but azathioprine carries significant monitoring requirements. The label warns of severe bone-marrow suppression, serious infections, hepatotoxicity, malignancies, and other adverse reactions (FDA, 2024a).
Important regulatory and clinical considerations include:
- Complete blood count monitoring.
- Liver-function monitoring.
- Dose adjustments for patients with reduced TPMT or NUDT15 activity.
- Interaction risk with allopurinol and febuxostat.
- Caution in pregnancy, infection, and malignancy-risk settings.
- Patient-specific assessment of the benefit-risk profile.
The FDA has recognized pharmacogenetic factors affecting azathioprine toxicity. TPMT and NUDT15 testing can help identify patients at higher risk of severe myelosuppression, although testing does not replace clinical monitoring.
How strong is the patent estate for Imuran?
The patent estate is commercially weak because the core molecule and conventional dosage form are old and genericized.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
None of current commercial significance |
| Remaining patent term |
None of practical significance |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Limited and not central to current sales |
| Manufacturing barriers |
Moderate operational relevance, low legal exclusivity |
| Regulatory exclusivity |
Expired |
| Generic substitution resistance |
Low |
| Brand pricing power |
Low |
The product can still have value as a recognized reference brand, but that value does not translate into durable patent-based revenue protection.
How does Imuran compare with competing immunosuppressants?
Azathioprine occupies a low-cost, established segment of the immunosuppression market. Its principal competitive threats are clinical alternatives, not patent challengers.
| Product or class |
Competitive position versus azathioprine |
| Tacrolimus |
Strong in transplant maintenance; often preferred in modern regimens |
| Mycophenolate mofetil |
Major transplant alternative with broad use |
| Methotrexate |
Alternative immunomodulator in rheumatology and autoimmune disease |
| Biologic therapies |
Stronger efficacy in selected inflammatory diseases, but higher cost |
| JAK inhibitors and targeted agents |
Newer alternatives in some autoimmune indications |
| Cyclosporine |
Older transplant competitor with toxicity and monitoring limitations |
| Azathioprine |
Low-cost, familiar, oral, and useful as a maintenance or steroid-sparing agent |
In inflammatory bowel disease, azathioprine competes with biologics, small-molecule therapies, and other immunomodulators. In transplantation, it has been displaced in many protocols by tacrolimus and mycophenolate, although it remains clinically relevant where cost, pregnancy considerations, tolerability, or patient history favor its use.
What is the market size and financial trajectory for Imuran?
A precise standalone Imuran revenue trajectory is not publicly available from major manufacturer disclosures. The brand has not generally been reported as a material independent revenue line in the way that a current patented specialty drug would be.
The financial trajectory is therefore characterized as follows:
| Period |
Financial profile |
| Early commercial period |
Branded product with higher pricing and limited direct competition |
| Generic-entry period |
Rapid price and market-share erosion |
| Mature generic period |
Low unit economics, fragmented supply, volume-driven revenue |
| Current period |
Brand revenue limited; molecule demand persists through generics |
| Forward outlook |
Stable-to-declining brand value, with generic demand tied to clinical use and supply |
Revenue exposure remains more relevant at the azathioprine-molecule level than at the Imuran-brand level. Demand is supported by the installed population of transplant recipients and patients receiving long-term immunomodulation. Volume is constrained by treatment migration to newer therapies and by concerns over cumulative toxicity.
What drives azathioprine market growth?
Positive demand drivers include:
- Low acquisition cost.
- Long clinical experience.
- Oral administration.
- Use in steroid-sparing regimens.
- Continued transplant demand.
- Use in countries with limited access to biologics.
- Familiarity among gastroenterologists, rheumatologists, dermatologists, and transplant physicians.
Negative drivers include:
- Generic price compression.
- Use of tacrolimus and mycophenolate in transplantation.
- Increased biologic penetration in autoimmune disease.
- Myelosuppression and malignancy warnings.
- TPMT and NUDT15-related safety concerns.
- Long treatment timelines and monitoring burden.
What generic launch scenarios exist for Imuran?
A conventional future generic launch would have limited strategic impact because generic azathioprine already exists. The more realistic scenarios are:
Baseline scenario
Multiple suppliers remain active, prices stay low, and Imuran retains limited brand recognition without meaningful pricing power.
Supply-consolidation scenario
One or more manufacturers exit, creating temporary shortages or price increases. This would improve generic supplier economics but would not restore patent exclusivity.
Clinical-substitution scenario
Transplant and autoimmune prescribing continues shifting toward newer agents. Azathioprine volume declines gradually while remaining important in cost-sensitive and selected clinical populations.
Manufacturing-disruption scenario
API constraints, plant issues, or regulatory action reduce available supply. Short-term market volatility could occur because the product is inexpensive and may have limited supplier redundancy in some regions.
Does Imuran have biosimilar risk?
Biosimilar risk does not apply directly to Imuran. Azathioprine is a synthetic small molecule, not a biologic. Its competitive risk comes from generic tablets and therapeutic substitutes, rather than biosimilar versions.
The relevant comparison is:
- Generic substitution for azathioprine.
- Therapeutic substitution with tacrolimus, mycophenolate, methotrexate, biologics, or targeted agents.
Biosimilar adoption can indirectly affect azathioprine by lowering the cost of biologic alternatives and making them more competitive in autoimmune disease.
What licensing deals affect Imuran?
No current licensing transaction is required to explain the commercial position of Imuran. The product is an old molecule with broad generic availability, and its economics are not dependent on a new platform license or proprietary delivery technology.
Brand rights, distribution rights, and regional trademarks may differ by country. Those arrangements can influence where the Imuran name appears, but they do not materially change the underlying generic economics.
What geographic markets remain important for azathioprine?
Azathioprine remains most commercially durable in markets where:
- Generic medicines dominate reimbursement.
- Biologic access is constrained.
- Transplant programs require lower-cost maintenance options.
- Physicians have long experience with thiopurines.
- National formularies prioritize older immunosuppressants.
The United States remains clinically important but is a low-value branded market. Europe and other developed markets have substantial generic penetration. Emerging markets can sustain unit demand, although pricing is generally lower and local regulatory requirements vary.
Key Takeaways
- Imuran is the original brand of azathioprine, a mature thiopurine immunosuppressant.
- U.S. regulatory and patent exclusivity expired decades ago.
- The current market is generic-driven, with limited brand pricing power.
- No active composition, formulation, or method-of-use patent is expected to create a meaningful commercial barrier.
- Paragraph IV litigation is historical rather than a current market driver.
- Biosimilar competition does not apply because azathioprine is a small molecule.
- Tacrolimus, mycophenolate, biologics, and targeted immunomodulators are the main competitive pressures.
- Standalone Imuran revenue is not publicly reported with sufficient consistency for a precise financial forecast.
- The brand outlook is stable-to-declining, while molecule-level demand should persist in transplantation, autoimmune disease, and cost-sensitive markets.
- The principal risks are price erosion, therapeutic substitution, supply disruption, and manufacturing concentration.
FAQs
Is Imuran still sold as a branded drug?
Imuran remains a recognized brand name in certain markets, but most azathioprine use is supplied through generic products. Brand availability and ownership vary by country.
Is azathioprine still used after kidney transplantation?
Yes. Azathioprine remains an immunosuppressive option, although tacrolimus and mycophenolate are commonly used in modern kidney-transplant regimens.
Can generic azathioprine replace Imuran?
Generic azathioprine is generally used as the therapeutic substitute for Imuran, subject to physician judgment, product availability, and local substitution rules.
Is Imuran a high-value pharmaceutical asset?
No. Its value is primarily tied to established demand, manufacturing reliability, and distribution. Patent-based exclusivity and premium branded economics are absent.
Does TPMT or NUDT15 testing affect azathioprine sales?
Testing can affect prescribing and dosing by identifying patients at higher risk of severe toxicity. It may reduce use in some patients while supporting safer use in others. The broader commercial effect is more likely to be improved treatment selection than significant market expansion.
References
- U.S. Food and Drug Administration. (2024a). Imuran (azathioprine) tablets: Prescribing information.
- U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. National Library of Medicine. (2024). DailyMed: Azathioprine and Imuran labeling.
- U.S. Food and Drug Administration. (2020). Table of pharmacogenetic associations: TPMT and NUDT15 with thiopurine toxicity.
- Kidney Disease: Improving Global Outcomes. (2009). KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation, 9(Suppl. 3).
